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Abstract
Background—In response to inconsistent findings, we investigated associations between 
maternal serum 25-hydroxyvitamin D (25(OH)D) concentrations and infant birthweight for 
gestational age (BW/GA), including potential effect modification by maternal race/ethnicity and 
infant sex.
Methods—Data from 2,558 pregnant women were combined in a nested case-control study 
(preterm and term) sampled from three cohorts: the Omega study, the Pregnancy, Infection and 
Nutrition study, and the Pregnancy Outcomes and Community Health study. Maternal 25(OH)D 
concentrations were sampled at 4 to 29 weeks’ gestation (80% 14–26 weeks). BW/GA was 
modeled as sex-and gestational age-specific birthweight z-scores. General linear regression 
models (adjusting for age, education, parity, pre-pregnancy body mass index, season at blood 
draw, and smoking) assessed 25(OH)D concentrations in relation to BW/GA.
Results—Among non-Hispanic Black women, the positive association between 25(OH)D 
concentrations and BW/GA was of similar magnitude in pregnancies with female or male infants 
(beta (β)=0.015, standard error (SE)=0.007, P=0.025; β=0.018, SE=0.006, P=0.003, respectively). 
Among non-Hispanic White women, 25(OH)D-BW/GA association was observed only with male 
infants and the effect size was lower (β=0.008, SE=0.003, P=0.02).
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Conclusions—Maternal serum concentrations of 25(OH)D in early and mid-pregnancy were 
positively associated with BW/GA among non-Hispanic Black male and female infants and non-
Hispanic White male infants. Effect modification by race/ethnicity may be due, in part, to overall 
lower concentrations of 25(OH)D in non-Hispanic Blacks. Reasons for effect modification by 
infant sex remain unclear.
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Recent research on maternal vitamin D levels in pregnancy raises questions about adequacy 
of maternal vitamin D levels for optimal perinatal outcomes.1 Some investigators have 
proposed that 27% to 91% of pregnant women in the United States have deficient or 
insufficient vitamin D levels due to lack of enough sunlight exposure or inadequate vitamin 
D intake.2 Non-Hispanic Black women are at higher risk for vitamin D deficiency because 
darker skin may limit vitamin D synthesis in the skin.3 A recent review reported that 
maternal vitamin D deficiency in pregnancy has been associated with gestational diabetes, 
preeclampsia, preterm delivery, and infants who are small for gestational age.4 The fetus 
largely depends on maternal sources of vitamin D.5 The impact of vitamin D on fetal growth 
may be mediated through vitamin D’s roles in calcium homeostasis, bone mineralization, 
and normal production and secretion of insulin.6
Epidemiologic findings on maternal vitamin D and fetal growth are inconsistent. Low 
birthweight and small for gestational age (SGA) are commonly used as proxy measures of 
fetal growth. Intervention trials of maternal vitamin D supplementation during pregnancy 
have reported mixed results with regard to effects on birthweight.7–10 Observational studies 
of vitamin D deficiency and fetal growth have likewise produced conflicting findings.11–24 
The diverse results may be due to varied study methodologies or different populations 
studied. Two studies noted a link between maternal vitamin D levels and fetal growth in 
non-Hispanic White women, but not in non-Hispanic Black women.11,14 The lack of 
association among non-Hispanic Blacks may be explained by small sample size and a 
relatively narrower distribution of vitamin D levels among non-Hispanic Blacks. One recent 
study observed effect modification by sex, with the vitamin D-fetal growth link occurring 
mainly among male offspring.25
We measured maternal serum 25-hydroxyvitamin D (25(OH)D) concentrations in a nested 
case-control (preterm-term) study assembled from three U.S. prospective cohort studies of 
pregnant women. Here we test the hypotheses that low maternal 25(OH)D concentrations in 
pregnancy are associated with decreased infant birthweight for gestational age (BW/GA) 
(operationalized as infant sex-and gestational age-specific birthweight z-scores), and this 
association is modified by maternal race/ethnicity and infant sex.
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Study design and population
This study uses data gathered in a nested case-control study of maternal 25(OH)D 
concentrations among preterm cases and matched term controls from three prospective 
cohort studies: the Omega study; the Pregnancy, Infection and Nutrition (PIN) study; and 
the Pregnancy Outcomes and Community Health (POUCH) study. Detailed descriptions of 
the cohorts are published elsewhere.26–28 In brief, the Omega study (1996–2008) examined 
determinants of preeclampsia, gestational diabetes, and other pregnancy outcomes of 
pregnant women recruited from prenatal care clinics affiliated with Swedish Medical Center 
in Seattle, Washington. The PIN study (1998–2005) investigated the roles of infection, 
stress, physical activity, and nutrition on risk of preterm delivery among pregnant women 
recruited from prenatal care clinics in central North Carolina. The POUCH study (1998–
2004) was designed to investigate infection, maternal vascular disease, and stress pathways 
to preterm delivery among pregnant women recruited from selected clinics in five Michigan 
communities. Human subjects approval for each study was granted by the Institutional 
Review Boards at the respective institutions.
Cohort protocols included maternal in-person interviews and/or self-administered 
questionnaires, and blood draws at enrollment. Maternal blood serum samples were frozen 
at -70°C and stored until analysis. Gestational age at enrollment was 4 to 23 weeks in the 
Omega study, 11 to 29 weeks in the PIN study, and 16 to 27 weeks in the POUCH study. 
Medical records were reviewed after delivery to obtain information on pregnancy course, 
perinatal events, and pregnancy outcome. In the original nested case-control study, preterm 
cases and term controls were matched within cohorts on maternal race/ethnicity, gestational 
week at blood draw, and season within a 45 day window of blood draw. Approximately 98% 
of cases were matched in a 1:2 ratio to controls; 2% were matched in a 1:1 ratio. The sample 
was limited to singleton pregnancies among non-Hispanic White and non-Hispanic Black 
women with information on infant sex, birthweight, and gestational week at delivery. After 
excluding women with outlier values for infant birthweight (n=1) or maternal 25(OH)D 
concentrations (n=7), the final sample size was 2,558 women (747 from Omega study, 977 
from PIN study, and 834 from POUCH study).
Outcome measurement
Infant sex- and gestational age-specific birthweight z-scores (BWz) were used to represent 
BW/GA. Infant birthweight (grams) and sex were abstracted from the hospital medical 
records. Calculation of gestational age (weeks) varied across studies: 1) In the Omega study 
and POUCH study, gestational age was calculated according to the first day of the self-
reported last menstrual period (LMP) or early ultrasound data from medical records. If both 
LMP and ultrasound dates were available and were within 14 days, LMP was used to 
determine gestational age. Otherwise, ultrasound gestational age estimates were used. In the 
PIN study, gestational age was determined by first ultrasound performed prior to 22 
completed weeks of gestation. If no ultrasound was performed prior to the start of week 22, 
then self-reported LMP was used to date the pregnancy. The BWz was calculated as 
(infant’s birthweight – mean birthweight of the gestational age and sex-specific stratum)/
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standard deviation of birthweight from the same stratum. The mean and standard deviation 
specific to each gestational age and sex stratum come from a referent population.29
Exposure measurement
Stored serum from the three cohorts was assayed in a single laboratory for hydroxyvitamin 
D2 (25(OH)D2) and hydroxyvitamin D3 (25(OH)D3) using liquid chromatography-tandem 
mass spectrometry with National Institute of Standards and Technology samples for quality 
control. The limit of detection was 1.1 ng/mL for 25(OH)D2 and 0.6 ng/mL for 25(OH)D3. 
The median intra-assay coefficients of variation were 7.1% (detectable range 1.4% to 
23.0%) and 6.9% (range 1.5% to 12.2%) for 25(OH)D2 and 25(OH)D3, respectively. The 
median inter-assay coefficients of variation were 13.5% (detectable range 3.0% to 28.7%) 
and 7.4% (range 1.4% to 14.3%) for 25(OH)D2 and 25(OH)D3, respectively. Both 
25(OH)D2 and 25(OH)D3 were combined for a measure of total serum 25-hydroxyvitamin 
D (25(OH)D), regarded as the best available biomarker of vitamin D status. In these 
analyses, total 25(OH)D is modeled as a continuous variable.
Covariates
Covariates of interest were maternal race/ethnicity (non-Hispanic Black, non-Hispanic 
White), maternal age, maternal education (high school or less, post high school), gestational 
age at blood draw, marital status (married, unmarried), parity (primiparous, multiparous), 
smoking status during pregnancy (yes, no), vitamins used during pregnancy (yes, no), 
season of blood draw, and pre-pregnancy body mass index (BMI). Less than 5% of women 
had missing data for any of these covariates, the largest number being for vitamin use 
(n=118) and smoking (n=54). Season of blood draw was classified as winter (December–
February), spring (March–May), summer (June–August), and fall (September–November). 
Pre-pregnancy BMI, calculated according to self-reported pregnancy height and weight, was 
categorized as underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25.0–
29.9 kg/m2), and obese (≥30 kg/m2) for descriptive statistics and was treated as a continuous 
measure in regression models.
Statistical analyses
The heterogeneity of cohort-specific estimates for 25(OH)D was assessed with the 
DerSimonian and Laird Q statistic, which indicated that the data could be combined across 
cohorts.30 Analysis of the distribution of 25(OH)D, using histograms and model fitting 
procedures, indicated it approximated a normal distribution. Analysis of variance (ANOVA) 
was performed to examine maternal characteristics associated with maternal 25(OH)D 
concentrations. Multivariable linear regression models were used to assess the association 
between maternal 25(OH)D concentrations and BWz. Covariates were incorporated in 
adjusted models if they: 1) showed associations with BW/GA and maternal 25(OH)D 
concentrations in the literature and in our data; 2) affected the magnitude of main effect 
estimates by greater than 10%; and 3) were not considered to be mediators. A model with 
25(OH)D and 25(OH)D squared tested the potential for nonlinearity in the 25(OH)D-
BW/GA association. Initially, separate analyses were performed for term and preterm 
deliveries for two reasons. First, the original study used a nested case-control design with 
preterm cases and term controls. Second, BWz scores for preterm infants use a mean that is 
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potentially biased downward (i.e., at a given gestational age a baby born preterm tends to be 
smaller than its counterpart who remains in-utero). Our goal was to examine if the 
25(OH)D-BW/GA association was similar in the two groups, term and preterm, and 
therefore could be combined.
Consistent with previous reports,11,14 we detected a significant difference in the distribution 
of 25(OH)D serum concentrations between race/ethnic groups; we tested effect modification 
by maternal race/ethnicity using an interaction term within a regression model. We next 
tested for interaction by infant sex within each race/ethnic stratum. Finally, we conducted 
sensitivity analyses by removing women with preeclampsia or gestational diabetes to assess 
if observed effects were largely explained by these pregnancy complications. Data are 
presented as beta (β) and standard error (SE) parameter estimates. All statistical tests were 
two-sided and a 5% level of significance was used throughout. Analyses were performed 
using SAS, version 9.3, Cary, North Carolina.
Results
The following maternal characteristics were associated with lower mean 25(OH)D 
concentrations: non-Hispanic Black race/ethnicity, <30 years of age, unmarried, pre-
pregnancy obesity, multiparity, smoking, and fewer years of education (Table 1). Women 
whose blood draw occurred from December to May, and who did not use vitamins during 
pregnancy also had lower mean 25(OH)D concentrations. Maternal 25(OH)D concentrations 
did not differ by infant sex (P=0.44). Figure 1 displays the distribution of maternal 25(OH)D 
concentrations in pregnancy by race/ethnicity; there is a left shift in non-Hispanic Black 
serum 25(OH)D concentrations compared to serum 25(OH)D concentrations in non-
Hispanic Whites.
In separate statistical models, a positive relationship between maternal 25(OH)D 
concentrations and BWz score was observed in both preterm and term deliveries; therefore 
the two were combined. We present results for the combined analyses and for the term only 
for comparison (Table 2). The unadjusted general linear regression analysis showed that 
BWz score increased by 0.012 (SE=0.002, P<0.001) per 1 ng/mL increase in maternal 
25(OH)D concentrations. The addition of a quadratic term for 25(OH)D did not significantly 
improve the model fit (data not shown). The linear association remained after adjustment for 
maternal age, education, parity, pre-pregnancy BMI, season, and smoking during pregnancy. 
Effect modification by maternal race/ethnicity was demonstrated using an interaction term in 
the regression model (P=0.04, results were unchanged after removing the Omega study 
which consisted of 37.56% non-Hispanic White women). Tests for effect modification by 
infant sex within each race/ethnic stratum suggested an interaction within the non-Hispanic 
White women only (P=0.11). A graphical representation reinforced this suggestion (Figure 
2). Among non-Hispanic Black women, the positive association between maternal 25(OH)D 
concentrations and BW/GA (BWz) was of similar magnitude in pregnancies with female or 
male infants (adjusted β=0.015, SE=0.007, P=0.025; β=0.018, SE=0.006, P=0.003, 
respectively) (Table 2). Among non-Hispanic White women, the 25(OH)D-BW/GA 
association was observed only with male infants and the magnitude was less (β=0.008, 
SE=0.003, P=0.02), approximately half that of non-Hispanic Black women.
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Analyses confined to term deliveries produced similar results, however, estimates were less 
stable due to limited statistical power. After removing women with preeclampsia or 
gestational diabetes, the positive association between maternal 25(OH)D concentrations and 
BWz scores persisted in all three of the four strata (data not shown).
Comment
This multi-cohort study found that maternal serum concentrations of 25(OH)D in early and 
mid-pregnancy were positively associated with BW/GA among non-Hispanic Black male 
and female infants and non-Hispanic White male infants. Comparison of our findings to 
those from previous studies of maternal 25(OH)D levels and BW/GA is challenging due to 
marked variation in study designs and analytic strategies across studies.
Results from studies examining maternal 25(OH)D concentrations and offspring 
birthweight, a measure affected by both fetal growth and gestational age at delivery, have 
been inconsistent. Observational studies following this approach have often failed to find an 
association.17–24 However, one multi-ethnic cohort study of 3,730 women in the 
Netherlands found significantly different mean birthweights for different 25(OH)D levels 
(<12 ng/mL: 3418g; <20 ng/mL: 3505g; ≥20 ng/mL: 3559g; P<0.001).31 A recent meta-
analysis of observational studies evaluating maternal 25(OH)D levels and pregnancy 
outcomes by Aghajafari et al. used a binary measure of 25(OH)D with a cutoff level of <15 
ng/mL.32 Their summary indicated that the low 25(OH)D group had significantly lower 
birthweight (mean difference −130.9 g; 95% confidence Interval (CI): −186.7, −75.1 g). 
Recently, data from three clinical trials were pooled by Thorne-Lyman et al.33 Results from 
this study suggested that 25(OH)D supplementation led to a significant 60% reduction in the 
risk of low birthweight. Another approach has been to study maternal 25(OH)D status and 
its relation to SGA, a categorical variable commonly used to denote fetal growth. A 
Netherlands-based cohort study showed that the odds of SGA among women with 25(OH)D 
<12 ng/mL was almost two-fold that of women with 25(OH)D ≥20 ng/mL (adjusted odds 
ratio (OR)=1.9, 95% CI: 1.4, 2.7).31 In the meta-analysis by Aghajafari et al., low 25(OH)D 
levels (<15 ng/mL) in pregnancy were associated with an increased risk of delivering an 
SGA infant, even after adjusting for potential confounders (pooled adjusted OR=2.1, 95% 
CI: 1.5, 2.7).32 In another meta-analysis by Wei et al., six observational studies, including 
6,013 women, were pooled.4 They found an increased risk of delivering an SGA infant 
among the low 25(OH)D group when the 25(OH)D cutoff level was <20 ng/mL (pooled 
OR=1.52, 95% CI: 1.1, 2.2), whereas there was no association detected with a 25(OH)D 
cutoff level of <30 ng/mL. Taken together, these studies support a positive association 
between maternal 25(OH)D levels and fetal growth, though the threshold of 25(OH)D for 
effect on fetal growth is uncertain.
In our study, the stronger association between 25(OH)D concentrations and BW/GA 
observed in non-Hispanic Black versus non-Hispanic White women may be due to a greater 
effect in the lowest end of the 25(OH)D distribution where there are limited data for non-
Hispanic Whites. Among other studies examining effect modification by race/ethnicity, 
Bodnar et al. reported evidence of a U-shaped association between maternal 25(OH)D levels 
and SGA in white women but not in non-Hispanic Black women.11 In Bodnar et al. nested 
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case-control study there was a relatively small sample of non-Hispanic Black women 
delivering SGA infants. Ertl et al. found that at 11–13 weeks’ gestation, 25(OH)D 
concentrations below 10th percentile were more common among pregnancies with SGA 
infants.14 This association was statistically significant in white women. In non-Hispanic 
Black women, the effect size was slightly less and sample size was limited for adequate 
statistical power. Our observed effect modification by race/ethnicity might also be explained 
by other factors associated with race/ethnicity that are also synergistic with vitamin D in 
their effects on fetal growth. Examples of these synergistic factors include maternal diet 
quality, physical activity, and pre-pregnancy vascular health. Among non-Hispanic White 
women in our study, the positive association between maternal 25(OH)D concentrations and 
BW/GA was confined to male infants, perhaps suggesting vulnerability for males, even 
within the moderately low 25(OH)D range. One previous study examined effect 
modification by infant sex and likewise reported a stronger association between maternal 
25(OH)D status and fetal growth in male offspring.25 The authors hypothesized that male 
and female infants respond differently to maternal nutritional stimuli, including maternal 
25(OH)D status.25
The biological plausibility of an association between maternal vitamin D levels and fetal 
growth rests on direct and indirect mechanisms. The fetus relies on maternal sources of 
vitamin D for bone remodeling and muscle function. Vitamin D is also involved in pathways 
that affect trophoblast invasion and angiogenesis, which are essential for adequate placenta 
implantation and fetal growth.4
From a clinical perspective, it may be helpful to translate our birthweight z-score results to 
birthweight differences between infants born to mothers with deficient vs sufficient levels of 
25(OH)D in pregnancy, defined here by Institute of Medicine (IOM) criteria.34 For example, 
among non-Hispanic Black male infants delivered at 40 weeks’ gestation (term), those born 
to mothers with a 25(OH)D level of 11ng/ml (the cutpoint for lowest quintile in this 
population of non-Hispanic Black mothers and considered deficient by IOM criteria) were, 
on average, 56g lighter than infants born to mothers with a 25(OH)D level of 20ng/ml (IOM 
cutpoint for sufficient). At 32 weeks’ gestation, this birthweight decrement is estimated to 
be, on average, 49g.
Our study had multiple strengths. By combining cohorts, the data included pregnant women 
from three different geographic areas in the United States, the sample size was relatively 
large, and the women represented diverse demographic characteristics. The large sample 
size and the diversity permitted an assessment of effect modification by maternal race/
ethnicity and infant sex. In addition, the 25(OH)D concentrations were measured by liquid 
chromatography-tandem mass spectrometry, which is currently the most accurate 
technique.35 A measure of serum 25(OH)D, with a half-life of about 2–3 weeks, reflects 
dietary and skin sources of the vitamin. Moreover, our study collected detailed data on 
several possible confounding variables. We used sex- and gestational age-specific 
birthweight z-scores as a proxy measure for fetal growth, instead of birthweight, which 
reflects a mixture of fetal growth and timing of delivery.
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There were also study limitations worth noting. Women’s 25(OH)D concentrations were 
measured only once and almost all measures were obtained before the third trimester. We do 
not know which trimester(s) in pregnancy are most relevant, but repeated measures of 
maternal 25(OH)D concentrations during pregnancy would be useful in future studies to 
examine this question. Due to the varying study protocols, the algorithm for determining 
gestational age across the three studies varied. Regardless of the small variation in 
approaches to calculating gestational age, results were rigorous enough to be consistent 
across the three population samples. The serum was assayed in 2011, thus some maternal 
blood samples were stored up to 15 years before being assayed for 25-Hydroxyvitamin D 
levels. However, if prolonged storage resulted in concentration decline it would be non-
differential and therefore our results may underestimate effect sizes. Because samples were 
obtained 7–19 years ago, they may not reflect the current distribution of maternal vitamin D 
levels. We lacked information on lifestyle factors, such as diet and physical activity, which 
could act as confounders. While maternal early and mid-pregnancy 25(OH)D concentrations 
may affect risk of pregnancy complications, pregnancy conditions associated with poor fetal 
growth might also influence maternal 25(OH)D status (reverse causation). We attempted to 
partially address this concern through our sensitivity analysis that removed women with 
preeclampsia and gestational diabetes and showed that results were relatively unchanged. 
We also lacked measure of vitamin D binding protein which can impact bioavailability of 
25(OH)D and may vary by race.36 Regrettably, we did not have adequate sample size to 
consider the categorical variable, SGA, in the context of the observed effect modifications 
by race/ethnicity and infant sex.
Our results suggest that low maternal 25(OH)D concentrations may affect BW/GA. 
However, further research is indicated to better understand the role of vitamin D in BW/GA 
and the adequate levels of maternal serum vitamin D needed for optimal fetal growth. The 
challenges of unmeasured confounding by multiple lifestyle factors and the recent 
controversy over the biological meaning of vitamin D status measured as total 25(OH)D 
suggest that observational studies alone cannot guide clinical practice.35 Large, well-
designed randomized controlled trials of vitamin D supplementation in pregnancy are 
needed to assess effects on fetal growth and health.
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The distribution of maternal 25-Hydroxyvitamin D (25(OH)D) concentrations by maternal 
race/ethnicity, three-cohort study, 1996–2008
Abbreviations: 25(OH)D, 25-hydroxyvitamin D
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The association between maternal 25-Hydroxyvitamin D (25(OH)D) concentrations and sex-
and gestational age-specific birthweight z-scores by maternal race/ethnicity and infant sex, 
three-cohort study, 1996–2008
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BWz, birthweight z-scores
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Table 1
Sample characteristics and the frequency distribution and mean 25-Hydroxyvitamin D (25(OH)D) 
concentrations (ng/mL), three-cohort study, 1996–2008
N (%)
25(OH)D concentrations (ng/mL)
Mean (SD) p-value a
25(OH)D concentrations 2558 29.6 (11.0)
Race/ethnicity <0.0001
non-Hispanic Black 641 (25) 20.2 (9.4)
non-Hispanic White 1917 (75) 32.7 (9.6)
Educationb <0.0001
High school or less 780 (31) 26.7 (12.0)
Post high school 1761 (69) 30.9 (10.3)
Age (years) <0.0001
<20 231 (9) 26.8 (11.3)
20–29 1100 (43) 28.6 (11.9)
30–39 1134 (44) 31.0 (10.0)
≥ 40 93 (4) 30.6 (8.5)
Marital statusb <0.0001
Married 1654 (65) 31.7 (10.0)
Unmarried 902 (35) 25.7 (11.7)
Gestation age at blood draw 0.01
(weeks) <14 227 (9) 28.1 (7.3)
14–26 2100 (82) 29.9 (11.2)
≥ 27 231 (9) 28.3 (12.3)
Season of blood draw <0.0001
December-February 592 (23) 28.3 (11.2)
March-May 736 (29) 27.2 (10.8)
June-August 607 (24) 32.7 (10.7)
September-November 623 (24) 30.5 (10.5)
Prepregnancy BMI
bc <0.0001
Underweight 117 (5) 29.8 (12.7)
Normal weight 1398 (55) 31.5 (10.3)
Overweight 506 (20) 29.1 (10.6)
Obese 530 (21) 25.2 (11.4)
Smoking status during pregnancyb 0.004
No 2029 (81) 29.9 (10.7)
Yes 475 (19) 28.3 (12.1)
Parityb <0.0001
Primiparous 1305 (51) 30.7 (10.2)
Multiparous 1252 (49) 28.4 (11.7)
Vitamins used during pregnancyb <0.0001
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N (%)
25(OH)D concentrations (ng/mL)
Mean (SD) p-value a
No 327 (13) 25.0 (12.0)
Yes 2113 (87) 30.5 (10.6)
Infant sex 0.44
Female 1258 (49) 29.4 (11.1)
Male 1300 (51) 29.8 (10.9)
Abbreviations: SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index
a
P-value for the global comparison test within the separate variables.
b
There are missing values for these variables; smoking is missing 54, vitamins used during pregnancy is missing 118, and the remainders are 
missing less than 20.
c
Underweight is <18.5 kg/m2, normal is 18.5–24.9 kg/m2, overweight is 25.0–29.9 kg/m2, and obese is ≥30 kg/m2.37
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